Subscribe to RSS
DOI: 10.1055/s-2002-32391
Möglichkeiten und Wertigkeit der kontrastverstärkten Ultraschalluntersuchung in der Beurteilung
von Lebererkrankungen
Contrast enhanced ultrasonography for the evaluation of liver diseases
Publication History
Publication Date:
20 June 2002 (online)
Zusammenfassung
Entwicklungen auf dem Gebiet der Ultraschall-Signalverstärker und der Ultraschall-Soft- und Hardware ermöglichen eine Steigerung der Sensitivität und Spezifität zum Nachweis und der Charakterisierung von Leberläsionen. Während viele Studien ein großes diagnostisches Potenzial der Echosignalverstärker nachgewiesen haben, ist die routinemäßige Verwendung des Kontrastmittelultraschalls noch nicht bis in den klinischen Alltag vorgedrungen. Dieser Review fokussiert auf allgemeine Aspekte der Kontrastmittel-Sonographie und ihre Verwendung für die Detektion und Charakterisierung von Leberläsionen und -erkrankungen.
Abstract
Recent advances in ultrasound contrast enhancing agents and in ultrasound soft- and hardware suggest increased sensitivity and specificity for the detection and characterization of hepatic lesions. While feasibility studies have shown the diagnostic potential of contrast enhancers in hepatic imaging, its use has not yet been implemented into clinical routine. This review focusses on the background of ultrasound contrast agents and their application for the detection and characterization of hepatic diseases and lesions.
Schlüsselwörter
Sonographie - Kontrastmittel - Leber - Raumforderungen - Harmonic Imaging
Key words
Ultrasound - Contrast agents - Liver - Lesions - Harmonic Imaging
Literatur
- 1 Delorme S. Radiological diagnosis of the liver. Radiologe. 2000; 40 904-915
- 2 Harvey C J, Albrecht T. Ultrasound of focal liver lesions. Eur Radiol. 2001; 11 1578-1593
- 3 Fischer G, Rak R, Sackmann M. Improved investigation of portal-hepatic veins by echo-enhanced Doppler sonography. Ultrasound Med Biol. 1998; 24 1345-1349
- 4 Skjoldbye B, Wieslander S, Struckmann J. et al . Doppler ultrasound assessment of TIPS patency and function - the need for echo enhancers. Acta Radiol. 1998; 39 675-679
- 5 Leutloff U C, Richter G M, Libicher M. et al . Follow-up of TIPSS by color-coded duplex sonography using an ultrasonic signal enhancer. First results. Radiologe. 1999; 39 1072-1077
- 6 Harvey C J, Blomley M J, Eckersley R J, Cosgrove D O. Developments in ultrasound contrast media. Eur Radiol. 2001; 11 675-689
- 7 Blomley M J, Cooke J C, Unger E C, Monaghan M J, Cosgrove D O. Microbubble contrast agents: a new era in ultrasound. Brit Med J. 2001; 322 1222-1225
- 8 Blomley M J, Albrecht T, Cosgrove D O. et al . Improved imaging of liver metastases with stimulated acoustic emission in the late phase of enhancement with the US contrast agent SH U 508A: early experience. Radiology. 1999; 210 409-416
- 9 Harvey C J, Blomley M J, Eckersley R J, Heckemann R A, Butler-Barnes J, Cosgrove D O. Pulse-inversion mode imaging of liver specific microbubbles: improved detection of subcentimetre metastases. Lancet. 2000; 355 807-808
- 10 Hübner G H, Steudel N, Reißmann A. et al . Hepatische arterielle Dopplersonographie mit dem Ultraschallsignalverstärker Levovist®: eine Placebo-kontrollierte, randomisierte Studie. Med Klin. 2001; 96 140 (Abstrakt)
- 11 Albrecht T, Urbank A, Mahler M. et al . Prolongation and optimization of Doppler enhancement with a microbubble US contrast agent by using continuous infusion: preliminary experience. Radiology. 1998; 207 339-347
- 12 Correas J M, Burns P N, Lai X, Qi X. Infusion versus bolus of an ultrasound contrast agent: in vivo dose-response measurements of BR1. Invest Radiol. 2000; 35 72-79
- 13 Gebel M, Caselitz M, Bowen-Davies P E, Weber S. A multicenter, prospective, open label, randomized, controlled phase IIIb study of SH U 508 a (Levovist®) for Doppler signal enhancement in the portal vascular system. Ultraschall Med. 1998; 19 148-156
- 14 Leutloff U C, Scharf J, Richter G M. et al . Use of the ultrasound contrast medium Levovist® in after-care of liver transplant patients. Improved vascular imaging in color Doppler ultrasound. Radiologe. 1998; 38 399-404
- 15 Strobel D, Krodel U, Martus P, Hahn E G, Becker D. Clinical evaluation of contrast-enhanced color Doppler sonography in the differential diagnosis of liver tumors. J Clin Ultrasound. 2000; 28 1-13
- 16 Uggowitzer M, Kugler C, Groll R. et al . Sonographic evaluation of focal nodular hyperplasias (FNH) of the liver with a transpulmonary galactose-based contrast agent (Levovist®). Br J Radiol. 1998; 71 1026-1032
- 17 Fracanzani A L, Burdick L, Borzio M. et al . Contrast-enhanced Doppler ultrasonography in the diagnosis of hepatocellular carcinoma and premalignant lesions in patients with cirrhosis. Hepatology. 2001; 34 1109-1112
- 18 Albrecht T, Blomley M, Burns P. et al . Vergleich von konventioneller Sonographie, KM-verstärkter Pulsinversions-Sonographie und 2 Phasen-Spiral-CT in der Detektion von Lebermetastasen: Ergebisse einer internationalen Multizenterstudie. Fortschr Röntgenstr. 2000; 172 92 (Abstrakt)
- 19 von Herbay A, Vogt C, Häussinger D. Phaseninversionssonographie in der Spätphase von Levovist® zur Differentialdiagnose zwischen benignen und malignen Leberrundherden. Z Gastroenterol. 2001; 39 743
- 20 Dill-Macky M J, Burns P N, Khalili K, Wilson S R. Focal hepatic masses: enhancement patterns with SH U 508A and pulse-inversion US. Radiology. 2002; 222 95-102
- 21 Blomley M J, Sidhu P S, Cosgrove D O. et al . Do different types of liver lesions differ in their uptake of the microbubble contrast agent SH U 508A in the late liver phase? Early experience. Radiology. 2001; 220 661-667
- 22 Kim J H, Kim T K, Kim B S. et al . Enhancement of hepatic hemangiomas with Levovist® on coded harmonic angiographic ultrasonography. J Ultrasound Med. 2002; 21 141-148
- 23 Caturelli E, Pompili M, Bartolucci F. et al . Hemangioma-like lesions in chronic liver disease: diagnostic evaluation in patients. Radiology. 2001; 220 337-342
- 24 Pompili M, Pignataro G, Rossi C. et al . Hyperechoic ultrasound (US) pattern of small hepatocellular carcinoma (HCC) in liver cirrhosis: prevalence and statistical correlations in 419 patients. Gut. 2001; 49 (Suppl III) 1982 (Abstrakt)
- 25 Tanaka S, Ioka T, Oshikawa O, Hamada Y, Yoshioka F. Dynamic sonography of hepatic tumors. Am J Roentgenol. 2001; 177 799-805
- 26 Choi B I, Kim A Y, Lee J Y. et al . Hepatocellular carcinoma: contrast enhancement with Levovist®. J Ultrasound Med. 2002; 21 77-84
- 27 Ohnishi K, Nomura F. Ultrasonic Doppler studies of hepatocellular carcinoma and comparison with other hepatic focal lesions. Gastroenterology. 1989; 97 1489-1497
- 28 Dodd G D , Memel D S, Baron R L, Eichner L, Santiguida L A. Portal vein thrombosis in patients with cirrhosis: does sonographic detection of intrathrombus flow allow differentiation of benign and malignant thrombus?. Am J Roentgenol. 1995; 165 573-577
- 29 Dusenbery D, Dodd G D , Carr B I. Percutaneous fine-needle aspiration of portal vein thrombi as a staging technique for hepatocellular carcinoma. Cytologic imdings of 46 patients. Cancer. 1995; 75 2057-2062
- 30 Choi B I, Kim T K, Han J K, Kim A Y, Seong C K, Park S J. Vascularity of hepatocellular carcinoma: assessment with contrast- enhanced second-harmonic versus conventional power Doppler US. Radiology. 2000; 214 381-386
- 31 Kim T K, Choi B I, Han J K, Hong H S, Park S H, Moon S G. Hepatic tumors: contrast agent-enhancement patterns with pulse-inversion harmonic US. Radiology. 2000; 216 411-417
- 32 Cioni D, Lencioni R, Bartolozzi C. Therapeutic effect of transcatheter arterial chemoembolization on hepatocellular carcinoma: evaluation with contrast-enhanced harmonic power Doppler ultrasound. Eur Radiol. 2000; 10 1570-1575
- 33 Solbiati L, Goldberg S N, Ierace T, Dellanoce M, Livraghi T, Gazelle G S. Radiofrequency ablation of hepatic metastases: postprocedural assessment with a US microbubble contrast agent - early experience. Radiology. 1999; 211 643-649
Dr. med. Klaus Schlottmann
Klinik und Poliklinik für Innere Medizin I Universitätsklinik
93042 Regensburg
Phone: 0941-944-7001
Fax: 0941-944-7002
Email: klaus.schlottmann@klinik.uni-regensburg.de